Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.07 BRL | -2.83% | -3.80% | -14.73% |
May. 08 | Transcript : Raia Drogasil S.A., Q1 2024 Earnings Call, May 08, 2024 | |
May. 07 | Raia Drogasil S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.99 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.73% | 8.2B | B | ||
-9.29% | 354M | - | ||
-0.43% | 264M | - | ||
+11.11% | 229M | - | - | |
-43.65% | 86.89M | C | ||
-10.09% | 86.36M | - | - | |
+28.26% | 61.19M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RADL3 Stock
- Ratings Raia Drogasil S.A.